Corvus Pharmaceuticals Newsroom

A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $13 to $24

Futu NewsNov 14 21:05

Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer

Dow JonesNov 13 22:52

Corvus Pharma Analyst Ratings

BenzingaNov 13 22:42

Corvus Stock Climbs 7% Following Mizuho Upgrade

Seeking AlphaOct 22 23:52

Mizuho Securities Upgrades Corvus Pharmaceuticals(CRVS.US) to Buy Rating, Announces Target Price $12

Futu NewsOct 22 18:37

Corvus Pharma Analyst Ratings

BenzingaSep 17 00:38

Ladenburg Thalmann Maintains Buy on Corvus Pharma, Raises Price Target to $21

BenzingaSep 17 00:38

Ladenburg Thalmann Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $21

Futu NewsSep 16 19:31

Analysts Have Conflicting Sentiments on These Healthcare Companies: Corvus Pharmaceuticals (CRVS), Vir Biotechnology (VIR) and Cooper Co (COO)

TipRanksAug 20 18:54

Corvus Pharma Analyst Ratings

BenzingaMay 7 20:10

Corvus Pharma Analyst Ratings

BenzingaApr 1 23:20

Hold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing Concerns

TipRanksMar 29 16:30

Corvus Pharma Analyst Ratings

BenzingaMar 28 01:25

Corvus Pharma Analyst Ratings

BenzingaMar 20 19:15

Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7

BenzingaMar 20 19:15

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Adaptimmune Therapeutics (ADAP) and Corvus Pharmaceuticals (CRVS)

TipRanksNov 10, 2023 19:40

Analysts' Opinions Are Mixed on These Healthcare Stocks: Editas Medicine (EDIT), Corvus Pharmaceuticals (CRVS) and AC Immune SA (ACIU)

TipRanksNov 8, 2023 14:41

Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Arcutis Biotherapeutics (ARQT) and Corvus Pharmaceuticals (CRVS)

TipRanksSep 12, 2023 23:40

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating

MT NewswiresSep 11, 2023 20:34

Cantor Fitzgerald Reiterates Overweight on Corvus Pharma, Maintains $4 Price Target

BenzingaSep 7, 2023 22:42